SCM
INBX icon

Soleus Capital Management’s Inhibrx INBX Stock Holding History

Soleus Capital Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-131,000
Closed -$8.81M – 105
2026
Q1 		$8.81M Buy
131,000
+106,000
+424% +$7.86M 0.36% 56
2025
Q4 		$1.98M Buy
+25,000
New +$1.7M 0.07% 80
2024
Q3 		– Sell
-88,470
Closed -$1.25M – 96
2024
Q2 		$1.25M Buy
+88,470
New +$1.38M 0.11% 82

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Soleus Capital Management's INBX Position: Q2 2026 in Review

Soleus Capital Management sold out of Inhibrx (INBX) in Q2 2026, closing a stake of 131,000 shares — an estimated $8.81M sold.

Soleus Capital Management first reported a position in INBX in Q2 2024 and held it in 3 quarters. The position peaked at $8.81M in Q1 2026. 163 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Soleus Capital Management reported no remaining Inhibrx position as of Q2 2026 after selling out during the quarter.
  • Soleus Capital Management sold 131,000 Inhibrx shares in Q2 2026, an estimated $8.81M.
  • Soleus Capital Management first reported a position in Inhibrx in Q2 2024 and held it in 3 quarters.
  • Soleus Capital Management's Inhibrx position peaked at $8.81M in Q1 2026.
  • 163 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Soleus Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.